Human IgG1 Fc protein (Recombinant) (No-Tag) (STJP019517)

SKU:
STJP019517
£127.50 - £851.50
Processing The item has been added

Short Description :Recombinant-Human IgG1 Fc-No-Tag protein was developed from hek293 cells and has a target region of No-Tag. For use in research applications.
Applications:SDS-PAGE/Bioactivity
Host:HEK293 Cells
Note:STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Concentration:1 mg/mL
Formulation:Liquid in phosphate-Buffered Saline (pH 7.4) containing 10% Glycerol
Storage Instruction:For short term storage, keep at +2C to +8C for up to 1 week. For long term storage, aliquot and store at-20C, and avoid repeat freeze-thaw cycles.
Endotoxin:< 1 EU per 1ug of protein (determined by LAL method)
Immunoreactivity:1. Measured by its binding ability in a functional ELISA with Human Fc gamma RIIIA/CD16a. The ED50 range ≤ 1.5 ug/ml.;; 2. Measured by its binding ability in a functional ELISA with Human Fc gamma RIIIA/CD16a.;; 3. Measured by its binding ability in
Gene Symbol:IGHG1Uniprot ID=IGHG1_HUMAN"
Accession Number:CAC20454.1
Immunogen:Human
Immunogen Region:100-330aa
Immunogen Sequence:PKSCDKTHTC PPCPAPELLG GPSVFLFPPK PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK ALPAPIEKTI SKAKGQPREP QVYTLPPSRD ELTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP VLDSDGSFFL YSKLTVDKSR WQQGNVFSCS VMHEALHNHY TQKSLSLS
Post Translational Modifications Glycosylation on Asn-180 is required for interaction with Fc receptors and ability to activate the complement pathway. (Microbial infection) Deglycosylation on Asn-180 by S.pyogenes EndoS or Endos2 endoglucosidases prevents interaction between immunoglobulin-gamma (IgG) and Fc receptors, impairing ability to activate the complement pathway.
Function Constant region of immunoglobulin heavy chains. Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens. The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen. Mediates IgG effector functions on monocytes triggering ADCC of virus-infected cells.
Protein Name Immunoglobulin Heavy Constant Gamma 1
Ig Gamma-1 Chain C Region
Ig Gamma-1 Chain C Region Eu
Ig Gamma-1 Chain C Region Kol
Ig Gamma-1 Chain C Region Nie
Cellular Localisation Isoform 1: Secreted
Isoform 2: Cell Membrane
Single-Pass Membrane Protein
Alternative Protein Names Immunoglobulin Heavy Constant Gamma 1 protein
Ig Gamma-1 Chain C Region protein
Ig Gamma-1 Chain C Region Eu protein
Ig Gamma-1 Chain C Region Kol protein
Ig Gamma-1 Chain C Region Nie protein
IGHG1 protein

Information sourced from Uniprot.org